Allogene Therapeutics, Inc. (ALLO) Q4 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Thank you for standing by. Welcome to Allogene Therapeutics' fourth quarter 2025 conference call. After the speaker's presentation, there'll be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be aware that today's conference call is being recorded. I would like to turn the call over to Christine Castellano, Chief Corporate Affairs and Brand Strategy Officer. Ms. Castellano, please go ahead. Thank you, Operator, and welcome everyone to AllerGene's conference call. After the market closed, AllerGene issued a press release that provided a business update and financial results for the fourth quarter and year-end 2025. This press release and today's webcast are available on our website. Following our prepared remarks, we will host a Q&A session and will aim to keep the call to under an hour. I'm joined today by Dr. David Chang, President and Chief Executive Officer, Dr. Zachary Roberts, Executive Vice President of Research and Development and Chief Medical Officer, and Jeff Parker, Chief Financial Officer. During today's call, we will be making certain forward-looking statements. These may include statements regarding the success and timing of our ongoing and planned clinical trials, data presentations, regulatory filings, future research and development efforts, manufacturing capabilities, the safety and efficacy of our product candidates, commercial market forecasts, and financial guidance, among other things. These forward-looking statements are based on current information, assumptions, and expectations that are subject to change. A description of potential risks can b...